BioCentury | Aug 10, 2018
Clinical News

Theravance's TD-9855 improves symptom severity in Phase II for hypotension

...symptomatic neurogenic orthostatic hypotension in Part C of a Phase II trial showing that once-daily TD-9855...
...out. In 13 patients who had a baseline OHSA Question #1 score of ≥4 points, TD-9855...
...Phase III trial of TD-9855 in the indication by year end or early next year. TD-9855...
BioCentury | May 5, 2014
Finance

Highlights of weekly biotech stock moves

...high-dose TD-9855 met the primary endpoint in the trial, while low-dose TD-9855 missed the endpoint. TD-9855...
BioCentury | May 5, 2014
Clinical News

TD-9855: Phase II data

...0.9 points, p=0.022). The once-daily 5 mg dose of TD-9855 missed the primary endpoint. High-dose TD-9855...
...a desirable outcome of identifying both effective and sub-effective dose of TD-9855." Both doses of TD-9855...
...events reported in the TD-9855 groups, with 1 assessed as possibly related to 5 mg TD-9855...
BioCentury | May 1, 2014
Clinical News

Theravance reports Phase II fibromyalgia data

...from a 392-patient Phase II trial evaluating once-daily TD-9855 to treat fibromyalgia. Once-daily 20 mg TD-9855...
...week of the six-week treatment period vs. placebo (p=0.022). The once-daily 5 mg dose of TD-9855...
...next steps for the compound in the indication. Last year, the company discontinued development of TD-9855...
BioCentury | Apr 7, 2014
Regulation

Confirming endpoints

..."That's the only way you can get a new medicine approved." Theravance Inc. is developing TD-9855...
BioCentury | Dec 16, 2013
Clinical News

TD-9855: Development discontinued

...Theravance disclosed in a November SEC filing that the company will discontinue development of TD-9855 to...
...or 20 mg oral TD-9855 for 6 weeks. Data from a Phase II trial evaluating TD-9855...
...molecules, including TD-9855 (see BioCentury, April 29). Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-9855...
BioCentury | Apr 29, 2013
Company News

Theravance infectious, gastrointestinal, pulmonary news

...receptor antagonist that has completed a Phase IIb trial to treat opioid-induced constipation (OIC); and TD-9855...
BioCentury | Apr 26, 2013
Company News

Theravance splitting up

...receptor antagonist that has completed a Phase IIb study to treat opioid-induced constipation (OIC); and TD-9855...
BioCentury | Dec 10, 2012
Clinical News

TD-9855: Phase II started

...Theravance began a placebo-controlled, double-blind, U.S. Phase II trial to evaluate 2 doses of once-daily TD-9855...
...to 9 weeks in about 375 patients. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-9855...
BioCentury | Dec 19, 2011
Clinical News

TD-9855: Phase II started

...Theravance began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 2 doses of oral TD-9855...
...in about 285 adult male ADHD patients. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Product: TD-9855...
Items per page:
1 - 10 of 10